Please ensure Javascript is enabled for purposes of website accessibility

Why Clovis Oncology's Stock Edged Higher in March

By George Budwell - Apr 7, 2017 at 4:53PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are clearly excited about Clovis' new ovarian cancer drug, but this enthusiasm may be overdone at this point.

What happened

According to data from S&P Global Market Intelligence, shares of Clovis Oncology (CLVS 5.26%) gained 7.42% in March. The drugmaker's shares are now up almost 28% so far this year due to the Food and Drug Administration's (FDA) approval of its advanced BRCA-mutant ovarian-cancer drug Rubraca last December.

This approval marked the second for a PARP inhibitor for advanced ovarian cancer, with AstraZeneca's (AZN -1.42%) Lynparza hitting the market first in 2014. PARP inhibitors function by interfering with a cell's ability to repair its DNA, leading to genomic instability and cell death. 

Doctor examining an x-ray.

Image Source: Getty Images.

So what

From a fundamental perspective, Rubraca should go a long way toward improving Clovis' outlook. With a high-end 2018 sales estimate of $462 million, for instance, Clovis could become a cash-flow-positive operation as early as next year.

Now what

The next shoe to drop is Rubraca's mid-year data release for its ongoing maintenance therapy study, dubbed "ARIEL 3."

Unfortunately for Clovis and its shareholders, though, Astra's Lynparza is currently under priority review with the FDA as a maintenance therapy in ovarian cancer, and Tesaro's (NASDAQ: TSRO) rival PARP inhibitor Zejula gained an early approval -- along with a far broader label than Rubraca -- just this week.

The point is that the advanced ovarian-cancer market is starting to get a tad crowded, and it's not altogether clear which drug will emerge as the market-share leader. Tesaro's drug, nonetheless, appears to have the best chance at grabbing the lion's share of the market based on its particularly strong clinical profile that prompted the FDA to approve it three months ahead of schedule. 

Clovis' run-up following Rubraca's approval may not be entirely warranted. Rubraca, after all, will have to overcome some stiff competition to justify the company's present valuation.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Clovis Oncology, Inc. Stock Quote
Clovis Oncology, Inc.
CLVS
$1.80 (5.26%) $0.09
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$66.07 (-1.42%) $0.95

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
317%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.